Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease -December 19, 2023 at 07:31 am EST

NEW YORK, Dec. 19, 2023 -- Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and...

Related Keywords

,Anavex Christopheru Missling ,Andrewj Barwicki ,Committee For Medicinal Products Human Use ,Company Nasdaq ,Nasdaq ,European Medicines Agency ,Linkedin ,Facebook ,Company On Twitter ,Union Marketing Authorisation ,Instagram ,Globenewswire Inc ,Research Business Development ,Michaelj Fox Foundation For Parkinson Research ,Anavex Life Sciences Corp ,Life Sciences ,Medicinal Products ,Human Use ,Medicines Agency ,Marketing Application ,Marketing Authorisation Application ,Christopheru Missling ,Chief Executive ,Annual Report ,Further Information ,Anti Amyloid Treatment ,Population Based Study ,Markets ,